Allan Dias Polverini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Allan Dias Polverini has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Daniel Antunes Moreno
Molecular Research Institute, Hospital de Cancer de Barretos, Fundação Pio XII, Barretos, Brazil
2 shared publications- Eduardo Mendes Correa
Neurosurgery, Department of Surgical Specialities, Pedro Ernesto University Hospital, State University of Rio De Janeiro, Rio de Janeiro, Brazil
2 shared publications - Gabriel Verly
Neurosurgery Department, Federal University of Rio de Janeiro, Rio de Janeiro, BRA
2 shared publications - Lucas Pari Mitre
Department of Neurosurgery, UT Southwestern Medical Center, Dallas, Texas
2 shared publications - Marcio Yuri Ferreira
Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, NY
2 shared publications - Miguel Vieira de Almeida
Ceará State University, Fortaleza, Brazil
2 shared publications
Latest Publications
- Open Access
- 27 February 2025
- Published by Elsevier in World Neurosurgery
- Vol. 197, 123842
Metformin as an Adjunct Treatment to Temozolomide for High-Grade Gliomas: A Systematic Review and Meta-Analysis
- 27 February 2025
- Published by Elsevier in World Neurosurgery
- Vol. 197, 123842
Open AccessMetformin as an Adjunct Treatment to Temozolomide for High-Grade Gliomas: A Systematic Review and Meta-Analysis
- 13 March 2024
- Published by Elsevier in World Neurosurgery
- Vol. 186, 17-26
Ultrasound-Guided Resection of High-Grade Gliomas: A Single-Arm Meta-Analysis
- 13 March 2024
- Published by Elsevier in World Neurosurgery
- Vol. 186, 17-26
Ultrasound-Guided Resection of High-Grade Gliomas: A Single-Arm Meta-Analysis
- 5 January 2024
- Published by Elsevier in World Neurosurgery
- Vol. 183, 239-245.e2
Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis
- 5 January 2024
- Published by Elsevier in World Neurosurgery
- Vol. 183, 239-245.e2
Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis
- Open Access
- 15 June 2022
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56 (4) , 205-211
EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
Background: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches.Methods: Spearman’s correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients’ samples, and was associated with clinicopathological data and overall survival.Results: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase–Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041).Conclusions: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology.
- 15 June 2022
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56 (4) , 205-211
Open AccessEGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
Background: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches.Methods: Spearman’s correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients’ samples, and was associated with clinicopathological data and overall survival.Results: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase–Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041).Conclusions: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology.